Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer; Report From the 2016 Coffey-Holden Prostate Cancer Academy Meeting.
The 2016 Coffey-Holden Prostate Cancer Academy (CHPCA) Meeting, "Beyond Seed and Soil: Understanding and Targeting Metastatic Prostate Cancer," was held from June 23 to June 26, 2016, in Coronado, California.



For the 4th year in a row, the Prostate Cancer Foundation (PCF) hosted the CHPCA Meeting, a think tank-structured scientific conference, which focuses on a specific topic of critical unmet need on the biology and treatment of advanced prostate cancer. The 2016 CHPCA Meeting was attended by 71 investigators from prostate cancer and other fields, who discussed the biology, study methodologies, treatment strategies, and critical unmet needs concerning metastatic prostate cancer, with the ultimate goal of advancing strategies to treat and eliminate this disease.



The major topics of discussion included: the molecular landscape and molecular heterogeneity of metastatic prostate cancer, the role of the metastatic microenvironment, optimizing immunotherapy in metastatic prostate cancer, learning from exceptional responders and non-responders, targeting DNA repair deficiency in advanced prostate cancer, developing and applying novel biomarkers and imaging techniques, and potential roles for the microbiome in prostate cancer.



This article reviews the topics presented and discussions held at the CHPCA Meeting, with a focus on the unknowns and next steps needed to advance our understanding of the biology and most effective treatment strategies for metastatic prostate cancer. Prostate 77:123-144, 2017. © 2016 Wiley Periodicals, Inc.
Prostate Cancer Foundation, Santa Monica, California.
Andrea K
AK
Miyahira
Comprehensive Cancer Center, Department of Internal Medicine, Ohio State University, Columbus, Ohio.|Division of Medical Oncology, Ohio State University, Cincinnati, Ohio.
Sameek
S
Roychowdhury
Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Sangeeta
S
Goswami
Department of Radiology, Washington University School of Medicine, St. Louis, Missouri.|Department of Genetics, Washington University School of Medicine, St. Louis, Missouri.
Joseph E
JE
Ippolito
Departments of Hematology and Hematopoietic Cell Transplantation, and Immuno-Oncology, Beckman Research Institute at City of Hope National Medical Center, Duarte, California.
Saul J
SJ
Priceman
Department of Laboratory Medicine, University of Washington, Seattle, Washington.
Colin C
CC
Pritchard
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.
Karen S
KS
Sfanos
Department of Genitourinary Medical Oncology, University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Sumit K
SK
Subudhi
Prostate Cancer Foundation, Santa Monica, California.
Jonathan W
JW
Simons
Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, Maryland.|Department of Urology, The James Buchanan Brady Urological Institute, Baltimore, Maryland.|Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland.
Kenneth J
KJ
Pienta
Prostate Cancer Foundation, Santa Monica, California.
Howard R
HR
Soule
D000047:Academies and Institutes / Q000639:trends*; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology; D002140:California; D032882:Comprehension; D003226:Congresses as Topic / Q000639:trends*; D016503:Drug Delivery Systems / Q000379:methods / Q000639:trends; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends*; D008297:Male; D011471:Prostatic Neoplasms / Q000235:genetics / Q000276:immunology / Q000628:therapy*; D058028:Research Report / Q000639:trends*; D059016:Tumor Microenvironment / Q000187:drug effects / Q000502:physiology
D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor
biomarkers; molecular imaging; therapeutics; tumor heterogeneity; tumor microenvironment